These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 22580782)

  • 21. Nocturnal polyuria and nocturnal arginine vasopressin (AVP): a key factor in the pathophysiology of monosymptomatic nocturnal enuresis.
    AbdelFatah D; Shaker H; Ismail M; Ezzat M
    Neurourol Urodyn; 2009; 28(6):506-9. PubMed ID: 19260089
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Changes of arginine vasopressin in elderly patients with acute traumatic cerebral injury.
    Huang WD; Yang YM; Wu SD
    Chin J Traumatol; 2003 Jun; 6(3):139-41. PubMed ID: 12749783
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Autosomal dominant polycystic kidney disease].
    Horie S
    Nihon Jinzo Gakkai Shi; 2011; 53(1):6-9. PubMed ID: 21370570
    [No Abstract]   [Full Text] [Related]  

  • 24. [The effect of hypervolemia on electrolyte level and and level of volume regulating hormones in patients with autosomal dominant polycystic kidney disease].
    Michalski A; Grzeszczak W
    Pol Arch Med Wewn; 1996 Oct; 96(4):329-43. PubMed ID: 9082344
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Relative Validity of a Beverage Frequency Questionnaire Used to Assess Fluid Intake in the Autosomal Dominant Polycystic Kidney Disease Population.
    Mannix C; Rangan A; Wong A; Zhang J; Allman-Farinelli M; Rangan G
    Nutrients; 2018 Aug; 10(8):. PubMed ID: 30096903
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease.
    Irazabal MV; Torres VE; Hogan MC; Glockner J; King BF; Ofstie TG; Krasa HB; Ouyang J; Czerwiec FS
    Kidney Int; 2011 Aug; 80(3):295-301. PubMed ID: 21544064
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Carbohydrate antigen 19-9 is significantly elevated in autosomal dominant polycystic kidney disease.
    Fukasawa H; Kaneko M; Niwa H; Yasuda H; Kumagai H; Furuya R
    Nephrology (Carlton); 2018 Mar; 23(3):210-216. PubMed ID: 28024168
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Plasma antidiuretic hormone in cases with the early onset of profound unilateral deafness.
    Takeda T; Kakigi A; Nishioka R; Taguchi D; Nishimura M
    Auris Nasus Larynx; 2008 Dec; 35(4):493-9. PubMed ID: 18329206
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical disorders of urine concentration and dilution.
    Harrington JT; Cohen JJ
    Arch Intern Med; 1973 Jun; 131(6):810-25. PubMed ID: 4574887
    [No Abstract]   [Full Text] [Related]  

  • 30. Hypertension, lipid abnormalities and cardiovascular changes in autosomal dominant polycystic kidney disease.
    Polat H; Karayaylali I; Niyazova Z; Seyrek N; Paydaş S; Sagliker Y
    Nephron; 1998; 78(3):369-71. PubMed ID: 9546713
    [No Abstract]   [Full Text] [Related]  

  • 31. Abdominal Respiration Induces Hemodilution and Related Reduction in ADH Concentration of Blood.
    Kawai Y; Ajima K; Nagai T; Yokoyama Y; Kaidoh M; Seto E; Honda T; Ohhashi T
    Lymphat Res Biol; 2015 Sep; 13(3):202-7. PubMed ID: 26305375
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Blood pressure, functional and morphological study of kidneys in children with autosomal dominant polycystic kidney disease].
    Seeman T; Vondrichová H; Strízová J; Sikut M; Janda J; Schärer K
    Cas Lek Cesk; 1999 Mar; 138(6):178-84. PubMed ID: 10510532
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The vasopressin system: new insights for patients with kidney diseases: Epidemiological evidence and therapeutic perspectives.
    Clark WF; Devuyst O; Roussel R
    J Intern Med; 2017 Oct; 282(4):310-321. PubMed ID: 28905441
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Unaltered Oxytocin and Vasopressin Plasma Levels in Patients with Schizophrenia After 4 Months of Daily Treatment with Intranasal Oxytocin.
    Busnelli M; Dagani J; de Girolamo G; Balestrieri M; Pini S; Saviotti FM; Scocco P; Sisti D; Rocchi M; Chini B
    J Neuroendocrinol; 2016 Apr; 28(4):. PubMed ID: 26715485
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Therapy for polycystic kidney disease? It's water, stupid!
    Grantham JJ
    J Am Soc Nephrol; 2008 Jan; 19(1):1-7. PubMed ID: 18032792
    [No Abstract]   [Full Text] [Related]  

  • 36. High serum soluble α-Klotho levels in patients with autosomal dominant polycystic kidney disease.
    Sari F; Inci A; Dolu S; Ellidag HY; Cetinkaya R; Ersoy FF
    J Investig Med; 2017 Feb; 65(2):358-362. PubMed ID: 27733443
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neurohypophysial peptides in guinea pig hypophysial portal blood: equimolar release of the carboxyl terminal glycopeptide with arginine vasopressin.
    Robinson IC; Fairhall KM; Dow RC; Fink G
    Neuroendocrinology; 1988 Jun; 47(6):575-80. PubMed ID: 3399037
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Proceedings: Plasma vasopressin and renal concentrating ability in the anaesthetized dog.
    Forsling ML; Ullmann E
    J Endocrinol; 1974 Nov; 63(2):41P-42P. PubMed ID: 4443703
    [No Abstract]   [Full Text] [Related]  

  • 39. Cyst expansion and regression in a mouse model of polycystic kidney disease.
    Happé H; van der Wal AM; Salvatori DC; Leonhard WN; Breuning MH; de Heer E; Peters DJ
    Kidney Int; 2013 Jun; 83(6):1099-108. PubMed ID: 23466997
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Postnatal development of renal concentration capacity as estimated by DDAVP-test in normal and asphyxiated neonates.
    Svenningsen NW; Aronson AS
    Biol Neonate; 1974; 25(3-4):230-41. PubMed ID: 4451694
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.